Abstract
Background: A growing body of evidence suggests that Hsp70, which is overexpressed in human breast tumors, plays a role in tumorigenesis and tumor progression in breast cancer as well as in its aggressive phenotypes. Hsp70 constitutes a potential therapeutic target in the treatment of this disease.
Methods: We developed a new series of rhodacyanine-based Hsp70 inhibitors, represented by compounds 1 and 6, in which the cationic pyridin-1-ium or thiazol-3-ium ring of existing Hsp70 inhibitors (e.g., JG-40 and JG-98) was replaced by a corresponding benzo- fused N-heterocycle.
Results: Several lines of evidence suggest that these benzo-fused derivatives may exert their antitumor activities, in part, by targeting Hsp70. These putative inhibitors displayed differential antiproliferative efficacy against breast cancer cells (IC50 as low as 0.25 μM) versus nontumorigenic MCF-10A breast epithelial cells (IC50 ≥ 5 μM). This was correlated with the corresponding Hsp70 expression levels. Using a protein refolding assay, we confirmed that these agents effectively inhibited the chaperone activity of Hsp70. Moreover, these inhibitors effectively suppressed the expression of well-known oncogenic client proteins of Hsp70’s, including FoxM1, HuR, and Akt, which paralleled their antiproliferative efficacy. Supporting the established role of Hsp70 in regulating protein refolding, these derivatives induced autophagy, as manifested by the conversion of LC3B-I to LC3B-II. Notably, these putative Hsp70 inhibitors did not cause a compensatory elevation in Hsp90 expression, contrasting with the previously reported effects of Hsp90 inhibitors on Hsp70 upregulation.
Conclusion: Together with the finding that compounds 1 and 6 showed improved microsomal stability, these results suggest the translational potential of these putative Hsp70 inhibitors to foster new strategies for cancer therapy. However, whether these benzo-fused rhodacyanines act on kinases or other targets remains unclear. It is currently under investigation.
Keywords: Hsp70 inhibitors, benzo-fused N-heterocycles, molecular chaperone, protein homeostasis, microsomal stability, anticancer.
Current Medicinal Chemistry
Title:Development of Novel Rhodacyanine-Based Heat Shock Protein 70 Inhibitors
Volume: 28 Issue: 26
Author(s): Chih-Shiang Chang, Vathan Kumar, Der-Yen Lee, Yeh Chen, Yu-Chieh Wu, Jing-Yan Gao and Po-Chen Chu*
Affiliation:
- Drug Development Center, China Medical University, Taichung 40402,Taiwan
Keywords: Hsp70 inhibitors, benzo-fused N-heterocycles, molecular chaperone, protein homeostasis, microsomal stability, anticancer.
Abstract:
Background: A growing body of evidence suggests that Hsp70, which is overexpressed in human breast tumors, plays a role in tumorigenesis and tumor progression in breast cancer as well as in its aggressive phenotypes. Hsp70 constitutes a potential therapeutic target in the treatment of this disease.
Methods: We developed a new series of rhodacyanine-based Hsp70 inhibitors, represented by compounds 1 and 6, in which the cationic pyridin-1-ium or thiazol-3-ium ring of existing Hsp70 inhibitors (e.g., JG-40 and JG-98) was replaced by a corresponding benzo- fused N-heterocycle.
Results: Several lines of evidence suggest that these benzo-fused derivatives may exert their antitumor activities, in part, by targeting Hsp70. These putative inhibitors displayed differential antiproliferative efficacy against breast cancer cells (IC50 as low as 0.25 μM) versus nontumorigenic MCF-10A breast epithelial cells (IC50 ≥ 5 μM). This was correlated with the corresponding Hsp70 expression levels. Using a protein refolding assay, we confirmed that these agents effectively inhibited the chaperone activity of Hsp70. Moreover, these inhibitors effectively suppressed the expression of well-known oncogenic client proteins of Hsp70’s, including FoxM1, HuR, and Akt, which paralleled their antiproliferative efficacy. Supporting the established role of Hsp70 in regulating protein refolding, these derivatives induced autophagy, as manifested by the conversion of LC3B-I to LC3B-II. Notably, these putative Hsp70 inhibitors did not cause a compensatory elevation in Hsp90 expression, contrasting with the previously reported effects of Hsp90 inhibitors on Hsp70 upregulation.
Conclusion: Together with the finding that compounds 1 and 6 showed improved microsomal stability, these results suggest the translational potential of these putative Hsp70 inhibitors to foster new strategies for cancer therapy. However, whether these benzo-fused rhodacyanines act on kinases or other targets remains unclear. It is currently under investigation.
Export Options
About this article
Cite this article as:
Chang Chih-Shiang , Kumar Vathan , Lee Der-Yen , Chen Yeh , Wu Yu-Chieh , Gao Jing-Yan and Chu Po-Chen *, Development of Novel Rhodacyanine-Based Heat Shock Protein 70 Inhibitors, Current Medicinal Chemistry 2021; 28 (26) . https://dx.doi.org/10.2174/0929867328666210203204254
DOI https://dx.doi.org/10.2174/0929867328666210203204254 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Learning from Bacteriophages - Advantages and Limitations of Phage and Phage-Encoded Protein Applications
Current Protein & Peptide Science The Application of Modified SBA-15 as a Chemosensor
Current Nanomaterials Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review
Infectious Disorders - Drug Targets COVID-19 Vaccine Race: Analysis of Age-Dependent Immune Responses against SARS-CoV-2 Indicates that more than Just One Strategy May Be Needed
Current Medicinal Chemistry Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales
Current Topics in Medicinal Chemistry Revisiting the South Indian Traditional Plants against Several Targets of SARS-CoV-2 - An <i>in silico</i> Approach
Current Computer-Aided Drug Design From Drug Target to Leads-Sketching A Physicochemical Pathway for Lead Molecule Design In Silico
Current Pharmaceutical Design Repurposing Ayush-64 for COVID-19: A Computational Study Based on Network Pharmacology and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Structural and Biochemical Investigation of Heptad Repeat Derived Peptides of Human SARS Corona Virus (hSARS-CoV) Spike Protein+
Protein & Peptide Letters Herbal Therapeutics as Potential Prophylaxis for SARS-CoV-2 Infection
The Natural Products Journal Pentraxins: CRP and PTX3 and Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review
Current Drug Targets Docking Paradigm in Drug Design
Current Topics in Medicinal Chemistry B-Cell Lymphoma Associated with COVID‐19 Infection: A Case Report
Current Medical Imaging The Impact of Combinatorial Methodologies on Medicinal Chemistry
Current Topics in Medicinal Chemistry Role of Microspheres in Drug Delivery-An Overview
Drug Delivery Letters Recent Developments on Phenstatins as Potent Antimitotic Agents
Current Medicinal Chemistry Coronavirus in the Arena: One More Time
Current Respiratory Medicine Reviews Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis
Current Medicinal Chemistry